6-K
Alcon Inc (ALC)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 6-K
_________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
February 13, 2023
Commission File Number: 001-31269
_________________
ALCON INC.
(Registrant Name)
Rue Louis-d'Affry 6 1701, Fribourg, Switzerland
(Address of principal executive office)
_________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40-F: Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit<br>Number | Description |
|---|---|
| 99.1 | Press release issued by Alcon Inc. dated February 12, 2023 titled “Alcon Announces Settlement of Litigation related to Femtosecond Laser Assisted Cataract Surgery Devices” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ALCON INC. | |||
|---|---|---|---|
| Date: | February 13, 2023 | By: | /s/ David J. Endicott |
| Name: David J. Endicott | |||
| Title: Authorized Representative | |||
| Date: | February 13, 2023 | By: | /s/ Timothy C. Stonesifer |
| Name: Timothy C. Stonesifer | |||
| Title: Authorized Representative |
3
Document
Alcon Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices
Ad Hoc Announcement Pursuant to Art. 53 LR
GENEVA, February 12, 2023 – Alcon Inc. ("Alcon") (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has entered into a settlement agreement with J&J Surgical Vision, Inc. to resolve their pending legal proceedings relating to femtosecond laser assisted cataract surgery devices, including Alcon’s LenSx® device, which Alcon acquired as part of its purchase of LenSx Lasers, Inc. in 2010. As part of the resolution of this matter, the parties have exchanged cross-licenses of certain intellectual property and other mutually agreed covenants and releases, and Alcon will make a one-time payment to J&J Surgical Vision, Inc. of USD 199 million for those rights and to resolve various worldwide intellectual property disputes relating to this matter.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.
Investor Relations
Dan Cravens
Allen Trang
41 589 112 110 (Geneva)
1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations
Steven Smith
41 589 112 111 (Geneva)
1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com